EMA/251126/2023

European Medicines Agency decision

P/0270/2023

of 14 July 2023

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one (BBP-671), (EMEA-003268-PIP01-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0270/2023

of 14 July 2023

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one (BBP-671), (EMEA-003268-PIP01-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Bridge Bio Europe B.V. on 30 June 2022 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 26 May 2023, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for 1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one (BBP-671), tablet, oral suspension, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for 1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one (BBP-671), tablet, oral suspension, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for 1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one (BBP-671), tablet, oral suspension, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Bridge Bio Europe B.V., 238 Herikerbergweg, 1101 CM – Amsterdam, The Netherlands.

EMA/PDCO/116648/2023 Corr[1]
Amsterdam, 26 May 2023

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-003268-PIP01-22

Scope of the application

Active substance(s):

1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one (BBP-671)

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of pantothenate kinase-associated neurodegeneration

Pharmaceutical form(s):

Tablet

Oral suspension

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Bridge Bio Europe B.V.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Bridge Bio Europe B.V. submitted for agreement to the European Medicines Agency on 30 June 2022 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 16 August 2022.

[1] 30 May 2023

Supplementary information was provided by the applicant on 16 February 2023. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of pantothenate kinase-associated neurodegeneration

The waiver applies to:

- the paediatric population from birth to less than 6 months of age;
- tablet, oral suspension, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

2. Paediatric investigation plan

2.1. Condition:

Treatment of pantothenate kinase-associated neurodegeneration

2.1.1. Indication(s) targeted by the PIP

Treatment of pantothenate kinase-associated neurodegeneration (PKAN)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 months to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Tablet

Oral suspension

2.1.4. Measures

Area	Description
Quality-related studies	**Study 1 (P-CRP-273036-R6)** Development of small tablets for use in patients aged 6 years to less than 18 years. **Study 2** Development of an age-appropriate oral liquid dosage form for use in children under 6 years of age.
Non-clinical studies	**Study 3 (20313227)** Definitive juvenile toxicity study in rats to evaluate the use of BBP-671 in the paediatric population.

Clinical studies	**Study 4 (CoA-201)** Randomised, double-blind, placebo-controlled trial to evaluate safety and efficacy of BBP-671 in patients from 6 years to less than 18 years of age (and adults) with pantothenate kinase-associated neurodegeneration (PKAN). **Study 5:** Open label, uncontrolled, single arm trial to evaluate safety and activity of BBP-671 in patients from 6 months to less than 18 years of age (and adults) with pantothenate kinase-associated neurodegeneration (PKAN).
Modelling and simulation studies	**Study 6:** Modelling and simulation, population pharmacokinetic (PopPK) study, to inform the dosing of the product in the treatment of pantothenate kinase-associated neurodegeneration (PKAN) in children from 6 years to less than 18 years of age. **Study 7:** Modelling and simulation, physiologically based pharmacokinetic (PBPK) study, to inform the dosing of the product in the treatment of pantothenate kinase-associated neurodegeneration (PKAN) in children from 6 months to less than 18 years of age.
Other studies	Not applicable
Extrapolation plan	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By October 2028
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.